Dinutuximab Beta in Children with High-Risk Neuroblastoma: Experience from a Single Center in Croatia

• Κύριοι συγγραφείς: Jasminka Stepan Giljević (Συγγραφέας), Nada Rajačić (Συγγραφέας), Danko Mikulić (Συγγραφέας), Ana Tripalo Batoš (Συγγραφέας)
• Μορφή: Βιβλίο
• Έκδοση: MDPI AG, 2022-06-01T00:00:00Z.
• Θέματα: article
• Διαθέσιμο Online: Connect to this object online.

To determine the potential benefits and feasibility of administering maintenance therapy with dinutuximab beta for high-risk neuroblastoma (HRNB) in clinical practice, a retrospective review of charts of patients with HRNB treated at a single center in Croatia (2012-2021) was undertaken. Of 23 patie...